After a national search, BioCrossroads has announced Patty Martin will become the life science initiative’s next president and chief executive officer. Martin, who most recently served as chief operating officer for Lilly Diabetes, will begin her new role Monday.
She will become just the third CEO in the organization’s 17-year history, and succeeds David Johnson, who in December announced plans to step down from the role to serve as president and CEO of the Central Indiana Corporate Partnership on a full-time basis.
"Patty understands how advancements in science can benefit the lives of millions of people around the world, and her long list of accomplishments demonstrates that fact. Her background is exactly what we need for the CEO of BioCrossroads, an organization nationally known for creating collaborations, answering life sciences market needs, and getting things done,” said Darren Carroll, board chair for BioCrossroads. "Her roles at Lilly in building teams and engaging stakeholders and colleagues will serve her very well in her new position."
Martin has spent more than 20 years at Eli Lilly and Co. (NYSE: LLY) and held a variety of roles, including chief diversity officer and chief alliance officer. She is also active in various Indianapolis nonprofits, the Indiana University Women’s Philanthropy Leadership Council and serving as board chair for the 2016 500 Festival.
"I’m passionate about the life sciences and the impact they can have on people and the community, particularly on Indiana," Martin said in a news release. "I’m honored to lead this organization and to continue its legacy of advancing the life sciences in the state by bringing together industry, academia and philanthropy in new and collaborative ways. Indiana has a rich life sciences history and an exciting future. It is my honor to advance the mission of BioCrossroads and ensure everyone is aware of the life-changing and life-saving work that is happening here."
Nora Doherty, who served as interim president and CEO during the search, will return to her role as senior vice president of BioCrossroads and managing director of the organization’s Seed Funds.